A Meta-analysis of the relation between chemokine receptor 5 delta32 polymorphism and multiple sclerosis susceptibility

References

• Barcellos LF, Schito AM, Rimmler JB, et al. (2000). CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics, 51, 281–8
   PubMed Web of Science ®Google Scholar
• Benkirane M, Jin DY, Chun RF, et al. (1997). Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem, 272, 30603–6
   PubMed Web of Science ®Google Scholar
• Bennetts BH, Teutsch SM, Buhler MM, et al. (1997). The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol, 58, 52–9
   PubMed Web of Science ®Google Scholar
• D'Angelo R, Crisafulli C, Rinaldi C, et al. (2011). CCR5Delta32 polymorphism associated with a slower rate disease progression in a cohort of RR-MS Sicilian patients. Mult Scler Int, 2011, 1--6
   Google Scholar
• Davey Smith G, Egger M. (1997). Meta-analyses of randomised controlled trials. Lancet, 350, 1182
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177–88
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. (1997). Bias in meta-analysis detected by a simple, graphical test. Br Med J, 315, 629–34
   PubMed Web of Science ®Google Scholar
• Favorova OO, Andreewski TV, Boiko AN, et al. (2002). The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology, 59, 1652–5
   PubMed Web of Science ®Google Scholar
• Favorova OO, Favorov AV, Boiko AN, et al. (2006). Three allele combinations associated with multiple sclerosis. BMC Med Genet, 7, 63
   Google Scholar
• Haase CG, Schmidt S, Faustmann PM. (2002). Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci Lett, 330, 293–5
   Google Scholar
• Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539–58
   PubMed Web of Science ®Google Scholar
• Hoppenbrouwers IA, Hintzen RQ. (2011). Genetics of multiple sclerosis. Biochim Biophys Acta, 1812, 194–201
   PubMed Web of Science ®Google Scholar
• Kaimen-Maciel DR, Reiche EM, Brum Souza DG, et al. (2007). CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int J Mol Med, 20, 337–44
   Google Scholar
• Kallaur AP, Kaimen-Maciel DR, Morimoto HK, et al. (2011). Genetic polymorphisms associated with the development and clinical course of multiple sclerosis (review). Int J Mol Med, 28, 467–79
   PubMed Web of Science ®Google Scholar
• Kantarci OH, Morales Y, Ziemer PA, et al. (2005). CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol, 169, 137–43
   PubMedGoogle Scholar
• Lee YH, Harley JB, Nath SK. (2006). Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet, 14, 364–71
   PubMed Web of Science ®Google Scholar
• Lee YH, Ji JD, Song GG. (2007). Tumor necrosis factor-alpha promoter -308 A/G polymorphism and rheumatoid arthritis susceptibility: A metaanalysis. J Rheumatol, 34, 43–9
   Google Scholar
• Lee YH, Witte T, Momot T, et al. (2005). The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: Two case-control studies and a meta-analysis. Arthritis Rheum, 52, 3966–74
   PubMed Web of Science ®Google Scholar
• Liu R, Paxton WA, Choe S, et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86, 367–77
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology, 46, 907–11
   PubMed Web of Science ®Google Scholar
• Luomala M, Lehtimaki T, Huhtala H, et al. (2003). Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand, 108, 396–400
   PubMed Web of Science ®Google Scholar
• Makarycheva OY, Tsareva EY, Sudomoina MA, et al. (2011). Family analysis of linkage and association of HLA-DRB1, CTLA4, TGFB1, IL4, CCR5, RANTES, MMP9 and TIMP1 gene polymorphisms with Multiple Sclerosis. Acta Naturae, 3, 85–92
   Google Scholar
• Nath SK, Harley JB, Lee YH. (2005). Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: A meta-analysis. Hum Genet, 118, 225–34
   PubMed Web of Science ®Google Scholar
• Prahalad S. (2006). Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: A meta-analysis. Genes Immun, 7, 264–8
   PubMed Web of Science ®Google Scholar
• Ristic S, Lovrecic L, Starcevic-Cizmarevic N, et al. (2006). No association of CCR5delta32 gene mutation with multiple sclerosis in Croatian and Slovenian patients. Mult Scler, 12, 360–2
   Google Scholar
• Sellebjerg F, Kristiansen TB, Wittenhagen P, et al. (2007). Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand, 115, 413–18
   Google Scholar
• Shahbazi M, Ebadi H, Fathi D, et al. (2009). CCR5-delta 32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol, 29, 1205–9
   Google Scholar
• Silversides JA, Heggarty SV, McDonnell GV, et al. (2004). Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler, 10, 149–52
   PubMedGoogle Scholar
• Szczucinski A, Losy J. (2007). Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand, 115, 137–46
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Kim J, Koch AE. (2003). Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol, 15, 15–21
   PubMed Web of Science ®Google Scholar
• Wedderburn LR, Robinson N, Patel A, et al. (2000). Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum, 43, 765–74
   PubMed Web of Science ®Google Scholar
• Wu L, LaRosa G, Kassam N, et al. (1997). Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med, 186, 1373–81
   PubMed Web of Science ®Google Scholar